DrugMapper
Browse
Therapeutic Area
CANCER (51)
CARDIOVASCULAR (45)
DENTISTRY (2)
DERMATOLOGY (31)
DIABETES DRUGS & ENDOCRINOLOGY (61)
EMERGENCY MEDICINE (3)
ENT (5)
EYE (23)
GASTROINTESTINAL (29)
HEMATOLOGY (23)
MUSCULOSKELETAL (28)
NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
PEDIATRICS (27)
PHARMACOLOGY (8)
PREGNANCY AND GYNECOLOGY (30)
RESPIRATORY (42)
RHEUMATOLOGY (19)
OTHER (1482)
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Primary Target
Target Level
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Active Pharmaceutical Ingredients (APIs)
Small Molecules
ProDrugs
Antibodies
CNS drugs
Metabolites
Search
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Target Sequence
Chemical Structure
Physicochemical Properties
Analyze
Networks
Chemical Similarity
Scaffold Similarity
KNIME workflow
Downloads
Web services
Bulk Downloads
About
DrugMapper FAQs
Data Sources
Contact Us
CETUXIMAB SAROTALOCAN
Search structure
Synonyms:
ASP-1929
Cetuximab-IRDye-700DX
Cetuximab-irdye 700dx conjugate
Cetuximab sarotalocan
RM-1929
Status:
Phase 1
Entry Type:
Antibody
Molecule Category:
UKNOWN
UNII:
MG94W1I5XW
Pharmacology
Action
Mechanism of Action
Reference
BINDING AGENT
Epidermal growth factor receptor erbB1 binding agent
PubMed
Other
Cross References
Resources
Reference
ChEMBL
CHEMBL4298088
FDA SRS
MG94W1I5XW
CONTENTS
Structure
Cross References
×
Active Pharmaceutical Ingredients (APIs)
Scaffolds
Exact
Similarity
SubStructure
Threshold (%) >=
70